Completed NA INTERVENTIONAL 2-arm NCT01132079

Pimecrolimus and Epidermal Barrier Function

Role for Pimecrolimus in Restoring Skin Barrier Function and Normalizing Epidermal Lipid Content and Differentiation in Atopic Epidermis: a Randomized, Intra-patient, Double-blind (Right/Left Arm) Study in Adults With Atopic Dermatitis Treated With 1 % Pimecrolimus Cream and 0.1 % Betamethasone Cream as Treatment Control Twice Daily for 3 Weeks

Sponsor: Deutsche Forschungsgemeinschaft, Bonn, Germany

Conditions Atopic Dermatitis

Interventions cream treatment

Updated 4 times since 2017 Last updated: May 26, 2010 Started: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01132079, this NA trial focuses on Atopic Dermatitis and remains completed. Sponsored by Deutsche Forschungsgemeinschaft, Bonn, Germany, it has been updated 4 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jan 2017 — Jan 2021 [monthly]

Completed NA

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Deutsche Forschungsgemeinschaft, Bonn, Germany
Novartis Pharma GmbH, Nürnberg, Germany
University of Kiel

Data source: University of Kiel

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kiel, Germany